oc
At ESGCT 2025, @Fesisisimo presented our results from a clinical trial of ALOCELYVIR in children with brain tumors, in a strong collaboration with Dr Álvaro Lassaletta and his team at Hospital Niño Jesús.
@APUpablougarte @AFANION_
@SaludISCIII
We are looking for a postdoctoral researcher with solid expertise in tumor immunology to join our group BIOC (ISCIII), dedicated to immuotherapies on pediatric cancer research.
This opportunity is linked to the AECC postdoctoral fellowships.
Feel free to contact us !!
Our group is presenting our latest results at the CICON25 Congress in Utrecht, a meeting with a special focus on immunotherapy of cancer
@SaludISCIII
In the pilot phase, no clinical responses were observed
in 18 patients unselected TILs.
However, when TILs were selected for neoantigen recognition, 3 responses were seen in 39 patients (7.7%).
Pembrolizumab
was added, and 8 objective responses were
seen in 34 patients (23.5%)
Osteosarcoma remains a highly aggressive bone malignancy with limited therapeutic options, necessitating novel treatment strategies.
Minireview:
frontiersin.org/journals/imm…
78
EsoBiotec SA has launched a clinical trial for ESO-T01, in vivo BCMA CAR-T therapy for multiple myeloma
ESO-T01 reprograms T cells directly using the ENaBL platform, which uses a viral vector said to be “immune shielded” via the removal of MHC1 and the overexpression of CD47
T cell receptor precision editing of regulatory T cells for
celiac disease.
Authors generated gluten- reactive HLA- DQ2.5–restricted CD4+ engineered eTregs.
e Tregs hold therapeutic potential for restoring gluten
tolerance in their mice model.
science.org/doi/epdf/10.1126…
"Donor-derived GD2-specific CAR T cells in
relapsed or refractory neuroblastoma."
Nat Med 2025
Bambino Gesù
Children’s Hospital, Italy.
nature.com/articles/s41591-0…
Phase I using B7-H3 CAR T cells for children with recurrent or refractory CNS tumors and DIPG.
Patients were treated on four escalating dose regimens: 1-10 × 10_7 CAR T cells per dose.
Authors did not find CRS complicating ICV infusions.
nature.com/articles/s41591-0…
Phase II clinical trial CT041-ST-01. An autologous CAR T-cell against Claudin18.2 (“satri-cel”, CT041) in advanced gastric cancers. Statistically significant improvement in progression-free survival (PFS) as compared to classic treatment.
carsgen.com/en/news/20241230…
Tumor-associated macrophages were the primary source of antigenic exposure governing the terminally exhausted T (Tex_term) to stem-like progenitor-exhausted T (Tex_prog) transition. TAM depletion promoted responsiveness to αPD1 immunotherapy.
cell.com/action/showPdf?pii=…
1
63
Haematopoietic gene therapy of non-conditioned patients with Fanconi anaemia-A: results from an open-label phase I/II and long-term clinical trials. Río, P.,.... , Bueren, J.A.. The Lancet, 2024, Vol 404
thelancet.com/journals/lance…
▶️New paper: "Deletion of the RGD motif from the penton base in oncolytic adenoviruses enhances antitumor efficacy of combined CAR T cell therapy"
We design ISC301, a novel oncolytic adenovirus, 🧬engineered to enhance immunotherapies. 💉
sciencedirect.com/science/ar…
Postdoctoral Junior Leader fellowships.
lacaixafoundation.org/en/pos…
Adaptimmune receives FDA accelerated approval of TECELRA, the first approved engineered cell therapy for a solid tumor: unresectable or metastatic synovial sarcoma expressing the MAGE-A4 antigen.
adaptimmune.com/investors-an…
FDA Accepts Mesoblast’s BLA for Ryoncil (remestemcel-L) in Children With Steroid-Refractory Acute GVHD
Remestemcel-L is an investigational therapy comprising culture expanded MSC derived from the bone marrow of an unrelated donor.
globenewswire.com/news-relea…
Satricabtagene autoleucel (satri-cel)/CT041 is an autologous CAR T cell targeting CLDN18.2
Nat Med (2024).
doi.org/10.1038/s41591-024-0…
In the largest report of #CARTcells in patients with solid tumors, autologous CLDN18.2-targeting CART therapy had overall response of 42.2% and disease control rate of 91.1% in patients with advanced CLDN18.2-positive gastrointestinal cancers
nature.com/articles/s41591-0…
























